UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Intracellular Neuroprotective Mechanisms in Neuron-Glial Networks Mediated by Glial Cell Line-Derived Neurotrophic Factor

Oxidative medicine and cellular longevity, 2019, Vol.2019 (2019), p.1-15

2019

Volltextzugriff (PDF)

RET fusions in solid tumors

Cancer treatment reviews, 2019-12, Vol.81, p.101911-101911, Article 101911

2019

Volltextzugriff (PDF)

Precision Targeted Therapy with BLU-667 for RET -Driven Cancers

Cancer discovery, 2018-07, Vol.8 (7), p.836-849

2018

Volltextzugriff (PDF)

RET revisited: expanding the oncogenic portfolio

Nature reviews. Cancer, 2014-03, Vol.14 (3), p.173-186

Mulligan, Lois M

2014

Volltextzugriff (PDF)

Glial-cell-derived neuroregulators control type 3 innate lymphoid cells and gut defence

Nature (London), 2016-07, Vol.535 (7612), p.440-443

2016

Volltextzugriff (PDF)

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

Cancer discovery, 2019-03, Vol.9 (3), p.384-395

2019

Volltextzugriff (PDF)

Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma

Modern pathology, 2015-04, Vol.28 (4), p.468-479

2015

Volltextzugriff (PDF)

RET rearrangements are actionable alterations in breast cancer

Nature communications, 2018-11, Vol.9 (1), p.4821-13, Article 4821

2018

Volltextzugriff (PDF)

Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers

Pharmacological research, 2018-02, Vol.128, p.1-17

2018

Volltextzugriff (PDF)

Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models

Cancer letters, 2013-10, Vol.340 (1), p.97-103

2013

Volltextzugriff (PDF)

ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry

Nature communications, 2019-12, Vol.10 (1), p.5622-15, Article 5622

2019

Volltextzugriff (PDF)

Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib

The Journal of biological chemistry, 2019-07, Vol.294 (27), p.10428-10437

2019

Volltextzugriff (PDF)

The importance of the RET gene in thyroid cancer and therapeutic implications

Nature reviews. Endocrinology, 2021-05, Vol.17 (5), p.296-306

2021

Volltextzugriff (PDF)

Foxo1 is required in mouse spermatogonial stem cells for their maintenance and the initiation of spermatogenesis

The Journal of clinical investigation, 2011-09, Vol.121 (9), p.3456-3466

2011

Volltextzugriff (PDF)

The neurotrophic factor receptor RET drives haematopoietic stem cell survival and function

Nature (London), 2014-10, Vol.514 (7520), p.98-101

2014

Volltextzugriff (PDF)

Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations

Clinical cancer research, 2019-10, Vol.25 (19), p.5832-5842

2019

Volltextzugriff (PDF)

The kinase PLK1 promotes the development of Kras / Tp53 -mutant lung adenocarcinoma through transcriptional activation of the receptor RET

Science signaling, 2022-10, Vol.15 (754), p.eabj4009

2022

Volltextzugriff (PDF)

Identification of ALK , ROS1 , and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients

Clinical chemistry (Baltimore, Md.), 2017-03, Vol.63 (3), p.751-760

2017

Volltextzugriff (PDF)

Neuronal Differentiation in Schwann Cell Lineage Underlies Postnatal Neurogenesis in the Enteric Nervous System

The Journal of neuroscience, 2015-07, Vol.35 (27), p.9879-9888

2015

Volltextzugriff (PDF)

GDF15: A Hormone Conveying Somatic Distress to the Brain

Endocrine reviews, 2020-08, Vol.41 (4), p.610

2020

Volltextzugriff (PDF)

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling

Molecular cancer therapeutics, 2017-08, Vol.16 (8), p.1623-1633

2017

Volltextzugriff (PDF)

RET signalling controls gut motility

Nature reviews. Gastroenterology & hepatology, 2024-02, Vol.21 (2), p.71-71

Ray, Katrina

2024

Volltextzugriff (PDF)

Therapeutic breakthroughs for metastatic thyroid cancer

Nature reviews. Endocrinology, 2020-02, Vol.16 (2), p.77-78

2020

Volltextzugriff (PDF)

Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology

Journal of medicinal chemistry, 2020-05, Vol.63 (9), p.4506-4516

2020

Volltextzugriff (PDF)

1 – 25 von 2.053

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.947)
Mit Volltextzugriff
(1.795)

Publikationsform

Artikel
(2.041)
Buchkapitel
(12)

Sprache

9 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.819)
Life Sciences & Biomedicine
(1.737)
Humans
(1.500)
Animals
(1.025)
Proto-Oncogene Proteins C-Ret - Genetics
(908)
Proto-Oncogene Proteins C-Ret
(826)
Male
(668)
Proto-Oncogene Proteins C-Ret - Metabolism
(667)
Female
(663)
Mice
(631)
Endocrinology & Metabolism
(600)
Drosophila Proteins
(573)
Receptor Protein-Tyrosine Kinases - Genetics
(571)
Thyroid Neoplasms - Genetics
(547)
Biological And Medical Sciences
(542)
Proto-Oncogene Proteins - Genetics
(534)
Mutation
(517)
Receptor Protein-Tyrosine Kinases - Metabolism
(410)
Adult
(388)
Oncology
(386)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Intracellular Neuroprotective Mechanisms in Neuron-Glial Networks Mediated by Glial Cell Line-Derived Neurotrophic Factor

RET fusions in solid tumors

Landscape of Acquired Resistance to Osimertinib in EGFR -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion

Precision Targeted Therapy with BLU-667 for RET -Driven Cancers

RET revisited: expanding the oncogenic portfolio

Glial-cell-derived neuroregulators control type 3 innate lymphoid cells and gut defence

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma

RET rearrangements are actionable alterations in breast cancer

Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers

Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models

ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry

Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib

The importance of the RET gene in thyroid cancer and therapeutic implications

Foxo1 is required in mouse spermatogonial stem cells for their maintenance and the initiation of spermatogenesis

The neurotrophic factor receptor RET drives haematopoietic stem cell survival and function

Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations

The kinase PLK1 promotes the development of Kras / Tp53 -mutant lung adenocarcinoma through transcriptional activation of the receptor RET

Identification of ALK , ROS1 , and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients

Neuronal Differentiation in Schwann Cell Lineage Underlies Postnatal Neurogenesis in the Enteric Nervous System

GDF15: A Hormone Conveying Somatic Distress to the Brain

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling

RET signalling controls gut motility

Therapeutic breakthroughs for metastatic thyroid cancer

Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology

Suchergebnisse filtern